Skip to main content
. 2022 Nov 26;58:102556. doi: 10.1016/j.redox.2022.102556

Fig. 2.

Fig. 2

Quantification of metabolites and predictive performance for CAP (A) Venn diagram: showing differential metabolites common to non-severe CAP and severe CAP disease groups. (B) Box-and-whisker plots of metabolites LPC 14:0 and LPC 16:1concentrations in CAP patients and healthy controls. The horizontal line represents the median; the bottom and the top of the box represent the bottom quartile and upper quartile; the whiskers represent the minimum and maximum values. (C) Spearman's correlations heatmap of biomarkers LPC 14:0, LPC 16:1, and clinical parameters. Red and blue indicate positive and negative correlations, respectively, and the darker the color, the stronger the correlation. (D) ROC curve analysis of the predictive performance of LPC 14:0, LPC 16:1, and various clinical parameters in non-severe CAP and severe CAP disease, respectively. (E) Evaluation of lung injury by H & E staining of lung tissue (Bar = 100 μm, magnification × 200) and the lung injury score. (F) Concentrations of LPC14:0 in serum and lung of control and ALI mice. * vs control, # AC vs RE, *p < 0.05, **p < 0.01, ***p < 0.001. CAP community-acquired pneumonia, NSCAP non-severe CAP, SCAP severe CAP, AC acute phase, RE remission phase. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)